KaloBios Pharmaceuticals (KBIO) Gravity or Reality; Voltari (VLTC) Impressive Bounce Back

KaloBios_Pharma_KBIO

After skyrocketed from around $2.00 to above $45.00 per share in the past 3 days of trading following an investment in the company by a group led by Martin Shkreli, KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) stock declined dramatically in value on Tuesday’s market activity

According to a regulatory filing ( 8-K ) with the SEC, KaloBios Pharmaceuticals received a delisting notice from NASDAQ due to its failure to satisfy the requirement for continued listing.

KBIO shares closed at $18.40, down $21.10 (or -53.42%)

KaloBios Pharmaceuticals, a biopharmaceutical company, has 4.12M Shares Outstanding, Market Capitalization (intraday) of $75.88M and KBIO stock 52-week range is from $0.44 to $45.82 per share

*

Voltari_ VLTC

Voltari Corp. (Nasdaq:VLTC) stock soared $5.07 (or +144.86%) to $8.57 on Tuesday’s trading session, and 21,267,881 of its shares exchanged hands during the day, a large increase in activity versus its average volume (3m) of 285,948

Billionaire investor Carl Icahn recently disclosed in an SEC filing ( 13F-HR ) a 52.3% stake (4,739,620 shares) in the company

Voltari, a digital advertising company, has 9.07M Shares Outstanding, Market Capitalization (intraday) of $77.72M and VLTC stock one-year range is between $0.63 and $21.75 per share

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/